Clinical Trials List
2021-11-01 - 2026-12-31
Phase III
Recruiting8
ICD-10C50.011
Malignant neoplasm of nipple and areola, right female breast
ICD-10C50.012
Malignant neoplasm of nipple and areola, left female breast
ICD-10C50.019
Malignant neoplasm of nipple and areola, unspecified female breast
ICD-10Z51.12
Encounter for antineoplastic immunotherapy
ICD-9174.0
Malignant neoplasm of female breast, nipple and areola
-
Trial Applicant
-
Sponsor
-
Trial scale
Multi-Regional Multi-Center
-
Update
2026/04/01
Investigators and Locations
Co-Principal Investigator
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- 阮昱翔 Division of Radiology
- Chun-Hsiu Liu Division of Ophthalmology
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- Chen-Teng Wu 未分科
- Yao-Chung Wu 未分科
- Liang-Chih Liu 未分科
- 黃至豪 未分科
- Chih-Jung Chen 未分科
The Actual Total Number of Participants Enrolled
0 Recruiting
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- Wei-Wu Chen 未分科
- MING-YANG WANG 未分科
- 張端瑩 未分科
- 黃柏翔 未分科
- 朱筱桑 未分科
- 陳怡君 未分科
- 羅喬 未分科
- 林季宏 未分科
- WEI-LI MA 未分科
- 林柏翰 未分科
The Actual Total Number of Participants Enrolled
0 Recruiting
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
The Estimated Number of Participants
-
Taiwan
納入ˋ40 participants
-
Global
納入700 participants
